Yes, bumetanide is highly protein bound
Bumetanide exhibits plasma protein binding in the range of 94% to 96% in adults, with approximately 97% binding documented in neonates 1. This high degree of protein binding is a critical pharmacokinetic characteristic that significantly impacts the drug's distribution, clearance, and clinical effects.
Key Protein Binding Characteristics
The protein binding profile of bumetanide has been well-characterized across different populations:
- Adult population: 94-96% protein bound 1, with one study reporting 95% binding 2 and another documenting 93% 3
- Neonatal population: Approximately 97% protein bound in cord sera from healthy neonates 1
- Critically ill neonates: Approximately 97% protein bound 4
Clinical Implications of High Protein Binding
Drug Interactions and Displacement
The extensive protein binding creates several clinically relevant considerations:
Bilirubin displacement in neonates: Bumetanide at concentrations of 0.5 to 50 mcg/mL causes a linear increase in unbound bilirubin concentrations in critically ill neonates 1. However, at presumed therapeutic plasma concentrations (0.5 mg/L), bumetanide displaces significantly less bilirubin than furosemide (1-2 mg/L), making it potentially safer in hyperbilirubinemic neonates 5.
Impact on Brain Penetration
The high protein binding (approximately 98%) severely limits bumetanide's ability to cross the blood-brain barrier 6. Combined with high ionization at physiological pH, this results in poor brain penetration, which has prompted development of lipophilic prodrugs for neurological applications 6.
Binding Site Characteristics
Ultrafiltration studies have identified two classes of binding sites 4:
- High-affinity, low-capacity site: k ~10³ M⁻¹, np ~10⁻³ M
- Low-affinity, high-capacity site: k ~10² M⁻¹, np ~10⁻² M
Both binding capacities exceed the presumed therapeutic concentration following intravenous administration (≤0.5 mcg/mL or ~10⁻⁶ M) 4.
Additional Pharmacokinetic Considerations
Beyond protein binding, bumetanide exhibits:
- Rapid elimination: Half-life of 1-1.5 hours in adults 1
- Renal clearance: Approximately 50% of total plasma clearance (228 mL/min) 3
- Urinary excretion: 81% of administered dose, with 45% as unchanged drug 1
- Efflux transport: Substrate of organic anion transporter 3 (OAT3), which further limits CNS penetration 7
The combination of high protein binding (94-97%), active efflux transport, and high brain tissue binding (77%) creates significant pharmacokinetic limitations for central nervous system delivery 7.